8-K: Progyny Reports Record Q1 2026 Revenue, Strong Demand

Progyny announced record first quarter 2026 revenue of $328.5 million, driven by robust demand for its women's health and family building solutions and a 12.2% increase excluding a former large client.

Summary

• Progyny reported record first quarter 2026 revenue of $328.5 million, a 1.4% increase year-over-year.
• Excluding the impact of a large client that did not renew, revenue increased by 12.2%.
• Gross profit rose 10% to $83.1 million, with gross margin improving to 25.3% from 23.4%.
• Net income increased to $24.2 million, or $0.29 per diluted share, up from $15.1 million, or $0.17 per diluted share, in the prior year.
• Adjusted EBITDA was $56.6 million, a slight decrease of 2.1% from $57.8 million in Q1 2025, with Adjusted EBITDA margin at 17.2%.
• The company repurchased 5.5 million shares for $116.4 million in the first quarter under its share repurchase program.
• Progyny anticipates having over 600 clients and approximately 7.2 million covered lives by the end of 2026.
• Full-year 2026 revenue is projected between $1.365 billion and $1.405 billion.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with record revenue and strong underlying growth, though a slight dip in Adjusted EBITDA due to strategic investments tempers an otherwise very strong outlook.

Positives

• Record first quarter revenue of $328.5 million.
• Significant revenue growth of 12.2% when excluding the impact of a former large client.
• Gross profit increased by 10% to $83.1 million.
• Gross margin improved by 190 basis points to 25.3%.
• Net income more than doubled to $24.2 million, with diluted EPS rising to $0.29.
• Strong operating cash flow of $45.9 million generated in the quarter.
• Continued robust demand for women's health and family building solutions, with early selling season activity reflecting favorable pipeline and commitments.
• Shareholder value returned through the repurchase of 8.8 million shares to date.

Negatives

• Adjusted EBITDA decreased by 2.1% to $56.6 million compared to the prior year period.
• Adjusted EBITDA margin decreased by 60 basis points to 17.2%.

Risks

• Potential for variability in member engagement due to macroeconomic uncertainty.
• Competition in the market.
• Unfavorable conditions in the industry or the U.S. economy.
• Difficulty in predicting future results due to limited operating history.
• Ability to attract and retain clients and increase service adoption.
• Loss of any of the largest client accounts.
• Changes in the technology or health insurance markets.
• Negative publicity in the health benefits industry.

Future Outlook

For the full year 2026, Progyny projects revenue between $1.365 billion and $1.405 billion, representing growth of 5.9% to 9.0% (10.1% to 13.3% excluding the former large client). Net income is projected between $103.7 million and $112.3 million, or $1.23 to $1.34 per diluted share. Adjusted EBITDA is expected to be between $232.0 million and $244.0 million. For the second quarter of 2026, revenue is projected between $342.0 million and $355.0 million, with Adjusted EBITDA expected between $58.0 million and $62.0 million.

Management Comments

• "We're pleased with the strong start to the year, as member engagement trended to the higher end of our expectations, reflecting that people are pursuing the services they need in order to address their family building and overall health and well-being goals."
• "These macro shifts reflect how society has increasingly deferred family building to later in life, when natural conception becomes more difficult for many, thereby increasing the demand for fertility benefits solutions that can cost-effectively address this fundamental need."
• "Our current selling season is in its early stages and we're off to a good start. Activity is healthy, overall pipeline and the early build of new pipeline is substantially favorable versus a year ago, and early commitments are pacing ahead of this time last year, all of which positions us well for this selling season."
• "This quarter's results reflect topline growth, increased gross margin, and a high conversion of Adjusted EBITDA to operating cash flow."
• "Additionally, through the share repurchase program that began in November, we returned value to our investors by repurchasing 8.8 million shares."

Industry Context

StockSavvy.ai notes that Progyny's results align with broader demographic trends of delayed family building, which is increasing demand for fertility and family planning benefits. The company's performance in a competitive market highlights the growing importance of specialized benefits solutions for employers.

Stakeholder Impact

• Shareholders: The company returned value through share repurchases and provided positive future outlook and guidance, which is generally favorable for shareholders.
• Employees: Planned investments in platform and member experience may indicate continued focus on employee tools and resources.
• Clients: Robust demand and continued client acquisition suggest satisfaction and value derived from Progyny's services.
• Members: Increased member engagement and focus on family building and health goals indicate continued utilization and benefit from Progyny's solutions.

Next Steps

• The Company's Board is currently evaluating potential options for a new share repurchase program and anticipates a decision and announcement around the end of May 2026.
• A handful of additional clients are expected to launch their benefits in the second quarter of 2026.
• Progyny will host a conference call on May 7, 2026, at 4:45 P.M. Eastern Time to discuss its financial results.

Key Dates

Recommendation

While the Q1 results show record revenue and strong underlying growth, the slight decrease in Adjusted EBITDA and the ongoing impact of losing a large client warrant a cautious approach. The positive outlook and strategic investments are encouraging, but the market may need to see sustained Adjusted EBITDA growth to justify a stronger recommendation. Therefore, a 'hold' position is prudent, awaiting further performance indicators.

Keywords

Progyny, Fertility Benefits, Family Building Solutions, Women's Health, Q1 2026 Earnings, Healthcare, Employee Benefits, Health Tech